Compare PGC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGC | CGEM |
|---|---|---|
| Founded | 1921 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.9M | 671.7M |
| IPO Year | N/A | 2021 |
| Metric | PGC | CGEM |
|---|---|---|
| Price | $27.89 | $10.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $37.00 | $27.14 |
| AVG Volume (30 Days) | 183.1K | ★ 1.3M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 6.12 | N/A |
| EPS | ★ 1.93 | N/A |
| Revenue | ★ $248,809,000.00 | N/A |
| Revenue This Year | $27.34 | N/A |
| Revenue Next Year | $16.59 | N/A |
| P/E Ratio | $14.49 | ★ N/A |
| Revenue Growth | ★ 18.63 | N/A |
| 52 Week Low | $23.96 | $5.68 |
| 52 Week High | $37.64 | $13.60 |
| Indicator | PGC | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 60.24 | 58.77 |
| Support Level | $26.37 | $10.01 |
| Resistance Level | $28.34 | $13.33 |
| Average True Range (ATR) | 0.84 | 1.07 |
| MACD | 0.30 | -0.00 |
| Stochastic Oscillator | 85.93 | 47.06 |
Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Wealth Management Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and Internet banking services. Wealth Management includes investment management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services. The services provided by the company include checking and savings accounts, money market and interest-bearing checking accounts, certificates of deposit, individual retirement accounts, and other services.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.